Ashkon Software







 

KZIA - Kazia Therapeutics Limited


KZIA Stock Chart

KZIA Profile

Kazia Therapeutics Limited logo

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

KZIA Revenue Chart


 

Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer